Print this page
-
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence.
Protocol: 042209Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast -
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.
Protocol: 032212Principal Investigator:
- Missak Haigentz MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lung -
Expanded Access Protocol: Umbilical Cord Blood Infusions for Children with Brain Injuries
Protocol: 112207Principal Investigator:
- Archana Sharma DO (Rutgers University)
Applicable Disease Sites: Other -
A Phase I/II Study of TheraT? Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers.
Protocol: 032213Principal Investigator:
- Missak Haigentz MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lung -
A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination with Hydroxychloroquine in Patients with Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations.
Protocol: 052216Principal Investigator:
- Sanjay Goel (Rutgers University)
Applicable Disease Sites: Anus
Small Intestine
Colon
Esophagus
Stomach
Rectum
Other Digestive Organ
Pancreas -
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy.
Protocol: 042211Principal Investigator:
- Coral Omene MD, PhD (Rutgers University)
Applicable Disease Sites: Breast